PMID- 25035208
OWN - NLM
STAT- MEDLINE
DCOM- 20140903
LR  - 20180718
IS  - 1879-355X (Electronic)
IS  - 0360-3016 (Linking)
VI  - 89
IP  - 5
DP  - 2014 Aug 1
TI  - Role of FDG-PET in the implementation of involved-node radiation therapy for 
      Hodgkin lymphoma patients.
PG  - 1047-1052
LID - S0360-3016(14)00497-0 [pii]
LID - 10.1016/j.ijrobp.2014.04.026 [doi]
AB  - PURPOSE: This study examines the role of (18)F-labeled fluorodeoxyglucose 
      positron emission tomography (FDG-PET) in the implementation of involved-node 
      radiation therapy (INRT) in patients treated for clinical stages (CS) I/II 
      supradiaphragmatic Hodgkin lymphoma (HL). METHODS AND MATERIAL: Patients with 
      untreated CS I/II HL enrolled in the randomized EORTC/LYSA/FIL Intergroup H10 
      trial and participating in a real-time prospective quality assurance program were 
      prospectively included in this study. Data were electronically obtained from 18 
      French cancer centers. All patients underwent APET-computed tomography (PET-CT) 
      and a post-chemotherapy planning CT scanning. The pre-chemotherapy gross tumor 
      volume (GTV) and the postchemotherapy clinical target volume (CTV) were first 
      delineated on CT only by the radiation oncologist. The planning PET was then 
      co-registered, and the delineated volumes were jointly analyzed by the radiation 
      oncologist and the nuclear medicine physician. Lymph nodes undetected on CT but 
      FDG-avid were recorded, and the previously determined GTV and CTV were modified 
      according to FDG-PET results. RESULTS: From March 2007 to February 2010, 135 
      patients were included in the study. PET-CT identified at least 1 additional 
      FDG-avid lymph node in 95 of 135 patients (70.4%; 95% confidence interval [CI]: 
      61.9%-77.9%) and 1 additional lymph node area in 55 of 135 patients (40.7%; 95% 
      CI: 32.4%-49.5%). The mean increases in the GTV and CTV were 8.8% and 7.1%, 
      respectively. The systematic addition of PET to CT led to a CTV increase in 60% 
      of the patients. CONCLUSIONS: Pre-chemotherapy FDG-PET leads to significantly 
      better INRT delineation without necessarily increasing radiation volumes.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Girinsky, Theodore
AU  - Girinsky T
AD  - Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France.
FAU - Auperin, Anne
AU  - Auperin A
AD  - Department of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif, 
      France.
FAU - Ribrag, Vincent
AU  - Ribrag V
AD  - Department of Medicine, Institut Gustave Roussy, Villejuif, France.
FAU - Elleuch, Manel
AU  - Elleuch M
AD  - Department of Imaging, Institut Gustave Roussy, Villejuif, France.
FAU - Ferme, Christophe
AU  - Ferme C
AD  - Department of Medicine, Institut Gustave Roussy, Villejuif, France.
FAU - Bonniaud, Guillaume
AU  - Bonniaud G
AD  - Department of Medical Physics, Institut Gustave Roussy, Villejuif, France.
FAU - Ruelle, Claude
AU  - Ruelle C
AD  - Department of Information Technology, Institut Gustave Roussy, Villejuif, France.
FAU - Alberini, Jean-Louis
AU  - Alberini JL
AD  - Department of Imaging, Institut Curie R. Huguenin Hospital, Saint-Cloud, France.
FAU - Celebic, Aljosa
AU  - Celebic A
AD  - Department of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif, 
      France.
FAU - Edeline, Veronique
AU  - Edeline V
AD  - Department of Imaging, Institut Curie R. Huguenin Hospital, Saint-Cloud, France. 
      Electronic address: veronique.edeline@curie.fr.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140708
PL  - United States
TA  - Int J Radiat Oncol Biol Phys
JT  - International journal of radiation oncology, biology, physics
JID - 7603616
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - 11056-06-7 (Bleomycin)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - ABVD protocol
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/therapeutic use
MH  - Bleomycin/administration & dosage
MH  - Confidence Intervals
MH  - Dacarbazine/administration & dosage
MH  - Diaphragm
MH  - Doxorubicin/administration & dosage
MH  - Female
MH  - *Fluorodeoxyglucose F18/pharmacokinetics
MH  - Hodgkin Disease/*diagnostic imaging/drug therapy/pathology/*radiotherapy
MH  - Humans
MH  - Lymph Nodes/*diagnostic imaging
MH  - Lymphatic Irradiation/*methods
MH  - Male
MH  - Middle Aged
MH  - Multimodal Imaging/methods
MH  - Positron-Emission Tomography/*methods
MH  - *Radiopharmaceuticals/pharmacokinetics
MH  - Tomography, X-Ray Computed/methods
MH  - Tumor Burden
MH  - Vinblastine/administration & dosage
MH  - Young Adult
EDAT- 2014/07/19 06:00
MHDA- 2014/09/04 06:00
CRDT- 2014/07/19 06:00
PHST- 2013/11/20 00:00 [received]
PHST- 2014/04/10 00:00 [revised]
PHST- 2014/04/15 00:00 [accepted]
PHST- 2014/07/19 06:00 [entrez]
PHST- 2014/07/19 06:00 [pubmed]
PHST- 2014/09/04 06:00 [medline]
AID - S0360-3016(14)00497-0 [pii]
AID - 10.1016/j.ijrobp.2014.04.026 [doi]
PST - ppublish
SO  - Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1047-1052. doi: 
      10.1016/j.ijrobp.2014.04.026. Epub 2014 Jul 8.